HDAC4 in ischemic stroke: Mechanisms and therapeutic potential

40Citations
Citations of this article
27Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Stroke is one of the leading causes of death and disability worldwide, and the majority of the cases are ischemic stroke. However, it still lacks effective treatment except for thrombolytic therapy in an extremely narrow time window. Increased evidence suggests that histone deacetylase 4 (HDAC4) was dysregulated in ischemic stroke, which plays a key role in the pathogenesis of ischemic stroke and post-stroke recovery by affecting neuronal death, angiogenesis, and neurogenesis. Therefore, we aim to review the dysregulation of HDAC4 in ischemic stroke and the role of dysregulated HDAC4 in the pathogenesis of ischemic stroke. Furthermore, the therapeutic potential of modulating HDAC4 in ischemic stroke is discussed.

Cite

CITATION STYLE

APA

Kong, Q., Hao, Y., Li, X., Wang, X., Ji, B., & Wu, Y. (2018, September 12). HDAC4 in ischemic stroke: Mechanisms and therapeutic potential. Clinical Epigenetics. BioMed Central Ltd. https://doi.org/10.1186/s13148-018-0549-1

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free